Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care
Article first published online: 22 JAN 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 3, pages 293–295, March 2010
How to Cite
Ward, M. M. (2010), Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care. Arthritis Care Res, 62: 293–295. doi: 10.1002/acr.20088
- Issue published online: 25 FEB 2010
- Article first published online: 22 JAN 2010
- Accepted manuscript online: 22 JAN 2010 12:00AM EST
- Manuscript Accepted: 15 DEC 2009
- Manuscript Received: 11 DEC 2009
- Intramural Research Program of the National Institute of Arthritis and Musculoskeletal Diseases
- 4US General Accounting Office. Medicare: payments for covered outpatient drugs exceed providers' cost. Washington (DC): US General Accounting Office; 2001.
- 5US District Court of Massachusetts. Pharmaceutical industry average wholesale price litigation: findings of fact and conclusions of law. 2007. URL: http://jimedwardsnrx.files.wordpress.com/2009/06/download-abbotts-motion-against-the-doj-here.pdf Findings of fact and conclusions of law.
- 8US Government Accountability Office. Medicare chemotherapy payments: new drug and administration fees are closer to providers' costs. Washington (DC): US Government Accountability Office; 2004.
- 10US House of Representatives: Ways and Means Committee, Subcommittee on Health. Medicare payments for currently covered prescription drugs: statement of the American College of Rheumatology. 2002. URL: http://waysandmeans.house.gov/Legacy/health/107cong/10-3-02/107-84final.htm.